+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline Review, H2 2019

  • ID: 4894135
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 87 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 1st Bio Therapeutics Inc
  • Arvinas Inc
  • Corestem Inc
  • EmeraMed Ltd
  • MitoDys Therapeutics Ltd
  • Neuropore Therapies Inc
  • MORE
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Multiple System Atrophy - Pipeline Review, H2 2019, provides an overview of the Multiple System Atrophy (Central Nervous System) pipeline landscape.

Multiple system atrophy (MSA) or Shy-Drager syndrome is a neurological disorder that impairs body's involuntary functions (blood pressure, heart rate, bladder function and digestion). Symptoms include rigid muscles, bradykinesia, Tremors, dysarthria, dysphagia, constipation, incontinence and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson's medications.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Multiple System Atrophy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Multiple System Atrophy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple System Atrophy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 9 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Multiple System Atrophy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple System Atrophy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Multiple System Atrophy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Multiple System Atrophy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Multiple System Atrophy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Multiple System Atrophy (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Multiple System Atrophy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Multiple System Atrophy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 1st Bio Therapeutics Inc
  • Arvinas Inc
  • Corestem Inc
  • EmeraMed Ltd
  • MitoDys Therapeutics Ltd
  • Neuropore Therapies Inc
  • MORE
Introduction
Report Coverage
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Overview
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Companies Involved in Therapeutics Development
1st Bio Therapeutics Inc
Alterity Therapeutics Ltd
Arvinas Inc
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Corestem Inc
Denali Therapeutics Inc
EmeraMed Ltd
ICB International Inc
Inhibikase Therapeutics Inc
MitoDys Therapeutics Ltd
Modag GmbH
Neuropore Therapies Inc
Newron Pharmaceuticals SpA
ProMIS Neurosciences Inc
Stealth BioTherapeutics Corp
United Neuroscience Ltd
Voyager Therapeutics Inc
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Drug Profiles
1ST-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anle-138b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit Alpha Synuclein for Parkinson's Disease and Multiple System Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIIB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-10BR05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emeramide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapies to Inhibit SNCA for Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IkT-148X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Alpha Synuclein for Multiple System Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Alpha Synuclein for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSA-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-20011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBT-434 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
safinamide mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBT-272 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Alpha Synuclein for Multiple System Atrophy and Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Neurodegenerative Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UB-312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
verdiperstat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Dormant Projects
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Product Development Milestones
Featured News & Press Releases
Nov 18, 2019: Alterity’s lead drug candidate receives positive opinion from European medical agency
Oct 17, 2019: Arvinas to Present update on Small Molecule to Inhibit Alpha Synuclein for Multiple System Atrophy and Parkinson's Disease at the 2nd Targeted Protein Degradation Summit
Sep 25, 2019: Alterity presents clinical data on PBT434 at the 2019 MDS Congress
Aug 01, 2019: Biohaven initiates enrolment in verdiperstat’s study for MSA
Jul 29, 2019: Alterity Therapeutics announces successful completion of phase 1 clinical trial
May 07, 2019: Biohaven provides update on verdiperstat from its MPO platform
May 06, 2019: Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting
May 03, 2019: Alterity Therapeutics presents at the American Academy of Neurology Annual Meeting
Apr 10, 2019: Alterity Therapeutics launches to Asian investors
Feb 19, 2019: Biohaven's Verdiperstat receives Orphan Drug Designation From FDA For multiple system atrophy
Jan 31, 2019: Prana receives Orphan Designation for PBT434 for treatment of MSA
Jan 23, 2019: Biohaven receives FDA may proceed letter for phase 3 clinical trial of BHV-3241 for multiple system atrophy
Mar 06, 2018: PBT434 poster presented at the 6th International Multiple System Atrophy Conference
Dec 04, 2017: ICBII Announces the Filing of Orphan Drug Designation Application for the Use of alpha-Synuclein-SMART Molecule in the Treatment of Multiple System Atrophy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by 1st Bio Therapeutics Inc, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Alterity Therapeutics Ltd, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Arvinas Inc, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Biogen Inc, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Corestem Inc, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Denali Therapeutics Inc, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by EmeraMed Ltd, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by ICB International Inc, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Inhibikase Therapeutics Inc, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by MitoDys Therapeutics Ltd, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Modag GmbH, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Neuropore Therapies Inc, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Newron Pharmaceuticals SpA, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by ProMIS Neurosciences Inc, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Stealth BioTherapeutics Corp, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by United Neuroscience Ltd, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Voyager Therapeutics Inc, H2 2019
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Dormant Projects, H2 2019

List of Figures
Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 1st Bio Therapeutics Inc
  • Alterity Therapeutics Ltd
  • Arvinas Inc
  • Biogen Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • Corestem Inc
  • Denali Therapeutics Inc
  • EmeraMed Ltd
  • ICB International Inc
  • Inhibikase Therapeutics Inc
  • MitoDys Therapeutics Ltd
  • Modag GmbH
  • Neuropore Therapies Inc
  • Newron Pharmaceuticals SpA
  • ProMIS Neurosciences Inc
  • Stealth BioTherapeutics Corp
  • United Neuroscience Ltd
  • Voyager Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll